Company / R&D Expense
TransMedics Group, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$69.1M
FY2025
5-year range
$22.3M / $69.1M
FY2021-FY2025
Trend
+23.4%
vs FY2024
Sector context
#70 of 105
Health Care
What the data says
At $69M, TransMedics Group, Inc.'s r&d expense ranks #70 of 105 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $19M in FY2020 to $69M in FY2025.
Based on SEC 10-K filings.
$69M in FY2025 with a 5-year CAGR of +29.7%.
Improved from $36M to $69M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +37.1%
- 5-Year CAGR
- +29.7%
- 10-Year CAGR
- -
Sector benchmark
#70 of 105 in Health CareTop 67% of 105This company $69.1M Sector average $284.2M
▼
-75.7% below sector average
Key checks
Key Insights
- TransMedics Group, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +29.7%, indicating consistent growth.
- In FY2025, r&d expense increased 23.4% year-over-year.
- Ranks #70 out of 105 companies in the Health Care sector.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $69.1M | +23.4% |
| FY2024 | $56.0M | +55.2% |
| FY2023 | $36.1M | +34.5% |
| FY2022 | $26.8M | +20.2% |
| FY2021 | $22.3M | +18.4% |
| FY2020 | $18.8M | -5.2% |
| FY2019 | $19.9M | +45.5% |
| FY2018 | $13.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026